All

We are pleased to share that Stromal Therapeutics have published groundbreaking research in Cell, shedding light on a critical interplay between fibroblasts and the local…

One of our preclinical companies is currently looking for an experienced biopharma entrepreneurial-minded CEO. The company specializes in engineering next-generation biologics to rebalance the immune…

Basel, Switzerland and Cambridge, MA – 9 Dec, 2024, Cimeio Therapeutics announced that it has entered a research collaboration with Kyowa Kirin Co., Ltd. (Kyowa…

MetaLead Therapeutics AG, a spin-out from the University of Zurich, is pioneering the field of metal-related diseases by focusing on novel therapeutic approaches for conditions…

Basel, Switzerland – 12 Nov, 2024, The BaseLaunch portfolio company Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and…

Synendos AG, a BaseLaunch portfolio company, has been awarded a prestigious grant under the Start-Up Innovation Project (SIP) scheme by Innosuisse. This highly competitive initiative…

Transitioning from early- to late-stage development is a pivotal phase for any biotech startup. This journey, often laden with both opportunities and challenges, requires a…

Basel, Switzerland – 2 Oct, 2024, Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced yesterday…

MT-act spun out from the Institute of Human Genetics and CNRS in Montpellier, leverages recent advances in understanding cytoskeleton stiffness and its influence on age-related…

We’re pleased to announce a partnership with Hoffmann & Partner AG, a well-regarded firm specializing in mergers & acquisitions (M&A) and CFO services. With over…